Who are Kerendia's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Slynd, Inspra, Flonase, Deoxycortone Pivalate, Dexamethasone Sodium Phosphate, Florinef.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/finerenone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Kerendia — Competitive Intelligence Brief

Kerendia (FINERENONE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal Mineralocorticoid-Receptor Antagonist [EPC]. Area: Metabolic.

marketed Nonsteroidal Mineralocorticoid-Receptor Antagonist [EPC] Mineralocorticoid receptor Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Kerendia (FINERENONE) — Bayer. Kerendia works by blocking the mineralocorticoid receptor, a protein that regulates sodium and potassium levels in the body.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Kerendia TARGET	FINERENONE	Bayer	marketed	Nonsteroidal Mineralocorticoid-Receptor Antagonist [EPC]	Mineralocorticoid receptor	2021-01-01
Slynd	DROSPIRENONE	Exeltis Usa Inc	marketed	Progestin	Mineralocorticoid receptor	2019-01-01
Inspra	EPLERENONE	Upjohn	marketed	Aldosterone Antagonist [EPC]	Mineralocorticoid receptor	2002-01-01
Flonase	fluticasone propionate	GSK (GlaxoSmithKline)	marketed	Inhaled/intranasal corticosteroid	Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor	1994-11-04
Deoxycortone Pivalate	DESOXYCORTICOSTERONE PIVALATE	Novartis	marketed	desoxycorticosterone pivalate	Mineralocorticoid receptor	1982-01-01
Dexamethasone Sodium Phosphate	dexamethasone phosphate	Merck & Co.	marketed	Corticosteroid	Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor	1959-01-01
Florinef	FLUDROCORTISONE ACETATE		marketed	fludrocortisone	Mineralocorticoid receptor	1955-01-01

Recent regulatory actions (last 90 days)

2026-03-03 — Flonase · FDA · approved · US · GSK (GlaxoSmithKline)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-08-26 — Flonase · 7500444*PED · Compound · US
2030-02-12 — Dexamethasone Sodium Phosphate · 8563027 · Method of Use · US
2030-05-14 — Dexamethasone Sodium Phosphate · 8409606 · Formulation · US
2031-02-14 — Flonase · 10195375 · Formulation · US
2031-04-04 — Flonase · 12083270 · Method of Use · US
2031-08-14 — Flonase · 10195375*PED · Compound · US
2032-05-11 — Dexamethasone Sodium Phosphate · 10799642 · Formulation · US
2034-05-23 — Dexamethasone Sodium Phosphate · 10028965 · Method of Use · US
2034-05-23 — Dexamethasone Sodium Phosphate · 10159683 · Formulation · US
2034-06-22 — Dexamethasone Sodium Phosphate · 10022502 · Method of Use · US
2035-12-14 — Flonase · 10918816 · Formulation · US
2036-02-23 — Flonase · 11554229 · Method of Use · US
2036-06-14 — Flonase · 10918816*PED · Compound · US
2036-10-07 — Dexamethasone Sodium Phosphate · 12150896 · Method of Use · US
2037-11-16 — Dexamethasone Sodium Phosphate · 11458041 · Method of Use · US
2037-12-18 — Dexamethasone Sodium Phosphate · 10537585 · Formulation · US
2037-12-18 — Dexamethasone Sodium Phosphate · 11304961 · Formulation · US
2039-06-23 — Dexamethasone Sodium Phosphate · 11097061 · Formulation · US
2039-08-20 — Flonase · 11969544 · Formulation · US
2039-09-26 — Flonase · 11344685 · Formulation · US
2040-02-20 — Flonase · 11969544*PED · Compound · US
2040-03-26 — Flonase · 11344685*PED · Compound · US
2040-07-06 — Flonase · 11173259 · Formulation · US
2041-01-06 — Flonase · 11173259*PED · Compound · US
2041-04-26 — Dexamethasone Sodium Phosphate · 12144889 · Method of Use · US

Sponsor landscape (Nonsteroidal Mineralocorticoid-Receptor Antagonist [EPC] class)

Bayer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Kerendia — Competitive Intelligence Brief. https://druglandscape.com/ci/finerenone. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab